Atezolizumab

製品コードA2004 別名: MPDL3280A

For research use only. Not for use in humans.

Atezolizumab is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1.

サイズ 価格(税別)  
JPY 117362.00

質量管理及び製品安全説明書

PD-1/PD-L1阻害剤の選択性比較

生物活性

製品説明 Atezolizumab is a fully humanized, IgG1 monoclonal antibody that blocks the interaction of PD-L1 with both PD-1 and B7.1, but not the interaction of PD-L2 with PD-1.
ターゲット
hPD-L1 [2]
(Cell-free assay)
0.4 nM(Kd)
体外試験

A key feature of atezolizumab is that it is FcγR-binding deficient, so it cannot bind to Fc receptors on phagocytes and therefore does not cause antibody-dependent cell-mediated cytotoxicity (ADCC). atezolizumab treatment could bring cytokine changes include transient increases in IL-18, IFNγ, and CXCL11, and a transient decrease in IL-6; cellular changes include increases in proliferating CD8+ T cells[1].

体内試験 By blocking the PD-L1/PD-1 immune checkpoint, atezolizumab reduces immunosuppressive signals found within the tumor microenvironement and consequently increases T cell mediated immunity against the tumor. The pharmacokinetics of atezolizumab were initially studied in cynomolgus monkeys and mice where its volume of distribution was calculated to be approximately that of the plasma volume. The in vivo biodistribution of atezolizumab 24 hours after infusion is, in order of magnitude, the spleen, lungs, kidneys, liver, heart, and muscle. In tumor bearing animals, the drug also accumulates intratumorally, initially at the pushing border of the tumor and progressing later to the tumor core, particularly if the tumor is necrotic. The pharmacokinetic curve of atezolizumab is dose-dependent (non-linear) because of target mediated drug disposition (binding of drug to the PD-L1 ligand in the body). Saturation of PD-L1 receptors by atezolizumab on circulating CD4 and CD8 T cells occurs between 24 and 48 hours after dosing with serum concentrations > 0.5 μg/mL[1]. MPDL3280A binds to PD-L1 in monkey and human with comparable affinity between species[2].

お薦めの試験操作(参考用のみ)

細胞試験:

[3]

+ 展開
  • 細胞株: DCCIKs lymphocytes
  • 濃度: 5 μg/mL
  • 反応時間: 24 h
  • 実験の流れ:

    The in vitro cytotoxicity of the DCCIKs used as effector cells in the absence or presence of 5 μg/mL MPDL3280A against CaSki cells employed as target cells at a ratio of 10:1, 30:1 and 90:1 was determined using a CCK8 kit. The effector and target cells were added to 96-well plates and incubated for 24 h. The groups comprising a mixture of cell types were the experimental groups, whereas the control groups contained only one cell type of the CaSki cells, DCCIKs or 1640 RPMI cultivating solution. The CCK8 assay was performed in triplicate and optical density (OD) was read at 570 nm.


    (Only for Reference)
動物試験:

[2]

+ 展開
  • 動物モデル: Cynomolgus monkeys
  • 製剤: 20 mM his-acetate, 0.02% polysorbate 20, 240 mM sucrose, pH 5.5
  • 反応時間: 0.5, 5 and 20 mg/kg
  • 実験の流れ: i.v.
    (Only for Reference)

製品説明

Formulation PBS buffer, pH 7.2
Isotype Human IgG
Source CHO cells
Storage Store at -80°C and avoid freeze-thaw cycles.

技術サポート

他の質問がある場合は、お気軽くお問合せください。

  • * 必須
Tags: Atezolizumabを買う | Atezolizumab ic50 | Atezolizumab供給者 | Atezolizumabを購入する | Atezolizumab費用 | Atezolizumab生産者 | オーダーAtezolizumab | Atezolizumab化学構造 | Atezolizumab分子量 | Atezolizumab代理店
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID